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Integration of miRNA and mRNA 
expression profiles reveals 
microRNA-regulated networks 
during muscle wasting in cardiac 
cachexia
Leonardo N. Moraes1, Geysson J. Fernandez1, Ivan J. Vechetti-Júnior1, Paula P. Freire1, 
Rodrigo W. A. Souza1, Rolando A. R. Villacis2,3, Silvia R. Rogatto4, Patricia P. Reis5, Maeli Dal-
Pai-Silva1 & Robson F. Carvalho1
Cardiac cachexia (CC) is a common complication of heart failure (HF) associated with muscle wasting 
and poor patient prognosis. Although different mechanisms have been proposed to explain muscle 
wasting during CC, its pathogenesis is still not understood. Here, we described an integrative analysis 
between miRNA and mRNA expression profiles of muscle wasting during CC. Global gene expression 
profiling identified 1,281 genes and 19 miRNAs differentially expressed in muscle wasting during CC. 
Several of these deregulated genes are known or putative targets of the altered miRNAs, including 
miR-29a-3p, miR-29b-3p, miR-210-5p, miR-214, and miR-489. Gene ontology analysis on integrative 
mRNA/miRNA expression profiling data revealed miRNA interactions affecting genes that regulate 
extra-cellular matrix (ECM) organization, proteasome protein degradation, citric acid cycle and 
respiratory electron transport. We further identified 11 miRNAs, including miR-29a-3p and miR-29b-3p, 
which target 21 transcripts encoding the collagen proteins related to ECM organization. Integrative 
miRNA and mRNA global expression data allowed us to identify miRNA target genes involved in 
skeletal muscle wasting in CC. Our functional experiments in C2C12 cells confirmed that miR-29b down-
regulates collagen genes and contributes to muscle cell atrophy. Collectively, our results suggest that 
key ECM-associated miRNAs and their target genes may contribute to CC in HF.
Heart failure (HF) is a major public health problem affecting millions of patients worldwide. As the most growing 
cardiovascular problem, HF affects about 2% of the Western population, with the prevalence increasing sharply 
from 1% in 40-year-old individuals to 10% above the age of 70 years1. It is the most common cause of hospitaliza-
tion with a poor prognosis similar to diseases such as cancer1–3. Cachexia associated with HF, or cardiac cachexia 
(CC), is a complex metabolic syndrome defined by a weight loss of > 6% over 6 months that accompanies HF in 
up to 50% of severe cases, being an independent factor of poor prognosis4, 5.
The awareness of CC has increased over the last two decades6, and several skeletal muscle alterations have 
been described in patients and animals with this condition; these include atrophy (wasting), shift from slow to fast 
fibers, decreased oxidative capacity, and increased fatigability7–11. Considering the overall complexity of skeletal 
muscle function regulatory mechanisms, processes that lead to progressive muscle wasting, ultimately resulting in 
CC, are likely due to deregulation of signaling networks. Previous examinations of large scale mRNA expression 
in human and rodent skeletal muscle atrophy have generated insights on the molecular changes underlying the 
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loss of skeletal muscle mass in different conditions such as unloading, immobilization, glucocorticoid treatment, 
diabetes, sarcopenia, starvation, and denervation12–17 and revealed new biomarkers of cancer cachexia18, 19.
Despite the pathophysiological stimuli for muscle wasting, different types of muscle atrophy may also share 
common transcriptional programs activated in systemic diseases20. Such complexity illustrates the need to apply 
a global approach to analyzing the molecular changes that occur during wasting in CC. Although global gene 
expression alterations are informative, the identification of microRNAs (miRNAs) has opened up a new field of 
investigation to understand molecular regulatory gene expression mechanisms in skeletal muscle diseases21–24. 
Comprehensive miRNA expression profiling has revealed that miRNA expression changes are associated with 
wasting conditions such as primary muscular disorders, dexamethasone-induced atrophy, fasting, denervation, 
diabetes, and cancer cachexia23–26. However, to our knowledge, no other study has examined the role of miRNAs 
in skeletal muscle wasting during HF and CC. Therefore, our goal was to perform an integrative, global miRNA 
and mRNA expression profiling analysis in soleus muscle of rats with CC to unravel novel regulatory networks 
and molecular pathways involved in muscle wasting. Studies such as this will provide the basis to understand the 
molecular regulatory mechanisms modulated by miRNAs in CC. Our data may be useful for future development 
of novel therapeutic approaches for preventing and treating muscle wasting in CC.
Results
Monocrotaline (MCT) treatment induces cardiac hypertrophy and failure. As expected, all rats 
that received intraperitoneal MCT injection developed right ventricular hypertrophy and failure (CC group) 
compared to control rats injected with saline (CT group) (Table 1). After 30 days of MCT injection, CC group 
exhibited signs of HF that included strong tachypnea, lack of spontaneous activity, piloerection and cold extrem-
ities before sacrifice. These animals also showed HF at post-mortem, confirmed by atrium and right ventricular 
hypertrophies, pleural and pericardial effusions, and presence of lung and liver congestion. No alterations were 
found in the control rats. Heart weight was increased in CC compared to CT, as demonstrated by right ventricle 
weight (RVW), atrium weight (ATW), and by the indexes of cardiac hypertrophy [left ventricle weight (LVW)/
body weight (BW), RVW/BW, and ATW/BW]. LVW was decreased in CC compared to CT; however, the LVW/
BW index was increased in CC.
MCT-treated rats develop CC associated with muscle wasting and fiber-type changes. Our 
findings are consistent with previous reports showing skeletal myopathy in HF (reviewed elsewhere27). 
MCT-treated rats develop CC associated with a significant reduction in whole BW (Table 1) and muscle fiber 
cross-sectional area (CSA; taken as an index of muscle atrophy) (Fig. 1A), confirming that these animals were also 
cachectic. The histochemical reaction of myofibrillar ATPase (m-ATPase) revealed a significant reduction in fiber 
CSA of all muscle-fiber types (I, II and Ic/IIc) in CC rats (Fig. 1A,B). These structural abnormality characteristics 
of skeletal myopathy related to CC also included qualitative changes in the content of muscular fibers second-
ary with a slow to fast transition in myofibrillar properties (Fig. 1C,D). Expression of the atrogenes Fbxo32 and 
Trim63 was increased in CC compared to CT; however, the expression of the myogenic regulatory factor Myod1 
was decreased (Fig. 1E). Additionally, gene expression analysis demonstrated reduced slow TnnI1 transcript levels 
despite no activation in the expression of fast TnnI2 or TnnT3 mRNAs in CC group (Fig. 1E).
Skeletal myopathy in cardiac cachexia is associated with transcriptome changes in key reg-
ulatory pathways. In order to understand the transcriptomic changes associated with skeletal myopa-
thy in CC, we performed a global mRNAs expression profiling analysis that identified 1,281 deregulated genes 
(p ≤ 0.01 and fold change ≥ 1.5), of which 538 and 743 were up- or down-regulated, respectively (Supplementary 
Table S1). Microarray data are available in Gene Expression Omnibus GSE72701, and the mRNA differentially 
expressed in CC are provided in the supplementary material. In most cases, a functional class was assigned to 
these 1,281 regulated genes using the Gene Set Enrichment Analysis (Supplementary Table S2). The top over- and 
under-expressed genes were selected and ranked by a combination of p-value < 0.05 and fold change ≥ 5, and are 
listed in Supplementary Tables S3 and S4, respectively.
CT CC P value
BW (g) 344.6 ± 17.5 255 ± 13.7 0.0022
LVW (g) 0.69 ± 0.03 0.60 ± 0.06 0.0152
LVW/BW (mg/g) 1.99 ± 0.17 2.35 ± 0.21 0.0260
RVW (g) 0.20 ± 0.03 0.49 ± 0.04 0.0022
RVW/BW (mg/g) 0.58 ± 0.06 1.94 ± 0.23 0.0022
ATW (g) 0.10 ± 0.01 0.19 ± 0.03 0.0022
ATW/BW (mg/g) 0.28 ± 0.03 0.76 ± 0.11 0.0022
Liver W/D 3.09 ± 0.04 3.53 ± 0.13 0.0002
Lung W/D 4.61 ± 0.19 4.98 ± 0.22 0.0219
Table 1. Anatomic data of CT and CC groups. Values are mean ± SD; n: number of animals; CT: control group 
(n = 6); CC: cardiac cachexia group (n = 6); BW: body weight; LVW: left ventricle weight; RVW: right ventricle 
weight; ATW: atrium weight; W/D, wet-to-dry weight. P value of the statistical significance difference between 
the groups.
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To determine the biological and functional implications of gene expression changes in muscle wasting during 
CC, we performed functional enrichment of the differentially expressed genes. This analysis showed that 30 path-
ways were clustered in biological processes important to skeletal myopathy in HF, which included structural genes 
(e.g., collagen biosynthesis, regulation of myotubes differentiation, extra-cellular matrix organization, and mus-
cle contraction), metabolic processes, cell death and proteolysis, and muscle growth and differentiation (Fig. 2). 
Other relevant processes enriched in our dataset included cytokine signaling, ion regulation and angiogenesis 
(Fig. 2).
To gain further insight into individual pathways, we also analyzed the over- and under-expressed genes in 
each pathway (Fig. 2). Notably, this analysis showed that all deregulated genes related to collagen biosynthesis 
were down regulated. The large majority of the deregulated genes related to cell proteolytic systems and cell death 
pathways were up regulated (Fig. 2).
Figure 1. Monocrotaline-treated rats develop right heart failure and cardiac cachexia associated with muscle 
wasting and fiber-type changes. Representative cross-sections of soleus muscles showing fiber-type distribution 
using myofibrillar adenosine triphosphatase (m-ATPase) reaction after pre-incubation at pH 4.3, from control 
(CT) and cardiac cachexia (CC) groups (A). CC decreases cross-sectional area (CSA; µm2) of fiber-types I, Ic/
IIc, and IIa (B), induces a slow-to-fast switch in fiber types composition (C), and changes the relative myosin 
heavy chain (MyHC) isoform percentage (%) in soleus muscle (D). Expression of atrogenes (Fbxo32 and 
Trim63), Myod, and slow and fast (Tnni1, Tnni2, and Tnnt3) myofiber genes in soleus muscle of CC compared 
to their levels of expression in CT (set at a value of 0), as detected by real-time PCR. Y-axis represents log2-fold 
change. The expression of each transcript was normalized by the expression of Ppib, B2m, and Ppia. (E) Data are 
expressed as mean ± SD; n = 6 per group. *p < 0.05; **p < 0.001: statistical significance versus CT group.
www.nature.com/scientificreports/
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miRNAs associated with skeletal myopathy in cardiac cachexia. To identify miRNAs as gene 
expression regulators in skeletal myopathy during CC, we performed a comparative miRNA expression profiling 
analysis. Eighteen of 373 miRNAs were differentially expressed in muscle wasting during CC compared to con-
trols (13 upregulated and 5 downregulated) (Fig. 3 and Supplementary Table S5).
Figure 2. Gene-term enrichment analysis of differentially expressed genes in soleus muscle of cardiac cachexia 
rats to identify top canonical pathways. Each vertical colored bars (y-axis) represent a major module; horizontal 
bars represent the percentage of genes presented in the data set compared to the total number of genes in 
each pathway. Fraction of DE genes in each pathway (up/down, red/blue; respectively) are shown in x-axis. 
Additional information in Supplementary Table S2.
Figure 3. Identification of differentially expressed miRNAs in soleus muscle of cardiac cachexia group (CC) 
compared to their level of expression in control group (CT; set at a value of 0), as detected by low-density 
miRNA arrays. Y-axis represents log2-fold change. The dashed line indicates fold change value of 1.5. The 
expression of each miRNA was normalized by the expression of the small RNAs snoRNA135, Y1, U87, and 
MammU6. Data are expressed as mean ± SD; n = 6 per group. *p < 0.05: statistical significance versus CT 
group.
www.nature.com/scientificreports/
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Integrative analyses of miRNA and mRNA expression profiles identified signaling pathways 
enriched with predicted miRNA targets. Since miRNAs regulate gene expression by both mRNA degra-
dation and translational repression mechanisms, and miRNA-mRNA regulatory networks are complex, we used 
a parallel miRNA-mRNA expression profile approach as previously described28–30 to increase the accuracy of our 
in silico mRNA target prediction used to identify potential mRNA targets of the differentially expressed miRNAs. 
A dataset of 1,281 genes generated from our mRNA microarray data with predicted and experimentally validated 
targets were paired to 18 differentially expressed miRNAs in CC. These miRNA–target relationships were pre-
dicted by at least four target prediction algorithms. To avoid target multiplicity, we constructed the miRNA tar-
get–gene network using differentially expressed genes identified by cDNA microarrays, considering that mRNA 
and miRNA expression levels should be inversely correlated if one regulates the other. We detected the next 
topology: 222 deregulations between 18 miRNAs and 177 target genes; the number and the overlap among these 
predicted targets for each miRNA are represented in Fig. 4.
Interestingly, the miRNAs miR-29a-3p and miR-29b-3p showed the higher number of overlapping targets 
mRNAs, including many transcripts that encode proteins related to extracellular matrix (ECM) (Supplementary 
Table S6). Moreover, we found that 95% of the deregulated miRNAs has at least 2 targets genes and that 10 
deregulated miRNAs have at least 10 targets genes (Supplementary Table S7). Indeed, we have found that the 
transcripts Fbxw7, Dnmt3a, and Ppic are co-deregulated by 3 or more miRNAs; including miR-29a-3p and miR-
29b-3p (Supplementary Table S8). As also shown in Fig. 4, most miRNA/mRNAs deregulations are connected, 
and generate a large connecting network. These results indicate an implicated combination of target multiplicity 
and miRNA cooperativeness during muscle wasting in CC.
Based on miRNA-target deregulated network analysis described above, we identified enriched pathways for tar-
get genes deregulated by differentially expressed miRNAs. As shown in the Fig. 5 and Supplementary Tables S4, 5 
pathways were enriched. Statistical comparisons revealed miRNA interactions affecting genes regulating ECM 
organization (P = 9.2E-5), proteasome protein degradation (P = 3.2E-5), citric acid cycle and respiratory electron 
Figure 4. Two distinct sub-networks miRNA-mRNA deregulated in cardiac cachexia. We identified 222 
deregulations between 18 miRNAs and 177 target genes. The solid lines connecting molecules represent 
miRNA-mRNA interaction. Node size represents number of targets for each miRNA, edge width denotes 
overlap between miRNAs measured by the Jaccard coefficient (JC), and nodes are colored based on the log2 fold 
change of the differential expression of the miRNA. The interaction network showed two smaller deregulated 
subnetworks that are clearly separate: one with 8 up-regulated miRNAs (in red) and the other with 4 down-
regulated miRNAs (in green) and each miRNA has multiple targets.
Figure 5. Gene-term enrichment analysis of mRNAs regulated by miRNAs in cardiac cachexia. Top canonical 
pathways affected in cardiac cachexia. Bars represent percentage of genes altered by miRNAs present in the data 
set compared to the total number of genes present in each selected pathway. In front of each bar is indicated the 
number of altered miRNAs in the pathway. Each color represents a major module.
www.nature.com/scientificreports/
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transport (P = 5.6E-4), JNK cascade (P = 3.4E-4) and cellular response to TGF-β (P = 7.8E-3). Interestingly, this 
analysis also revealed 11 miRNAs, including miR-29a-3p and miR-29b-3p, which target 21 transcripts encod-
ing proteins related to ECM, comprising the collagens Col1a1, Col1a2, Col22a1, Col3a1, Col5a1, and Col6a2 
(Supplementary Table S4).
To elucidate the functions of these complex interactions between mRNAs and miRNAs in the ECM network, 
we further examined probable miRNA-mRNA interactions. The complexity of the miRNA-mRNA interactome 
of muscle wasting in CC is demonstrated by a regulatory network displaying predicted and validated interac-
tions between deregulated miRNAs and target mRNAs that are enriched, considering physical and pathway 
protein-protein interactions using Cytoscape database (Fig. 6). This analysis further confirmed the importance 
of miR-29 family members and their interaction with ECM protein coding transcripts. Our data highlight, for 
the first time, a set of miRNAs that targets transcripts that encode ECM organization proteins in muscle wasting 
during CC.
Extracellular matrix remodeling in cardiac cachexia. The high degree of consistency in the pathway 
enrichment analyses clearly suggests that CC induces coherent interactions between the miRNAs and mRNAs 
involved in ECM. The ECM remodeling was confirmed by changes in both collagen gene (Fig. 7A) and protein 
expression (Fig. 7B,C). Corroborating these data, the cross-sectional analysis of the soleus muscle stained by 
Picrosirius technique demonstrated a relative decrease of collagen content in the ECM (Fig. 7D,E). Next, we 
asked whether miR-29b mediates the repression of Col1a1 and Col3a1 expression with a functional consequence 
in muscle cells atrophy. To test this, we transfected a synthetic miR-29b mimic into C2C12 myoblasts that were 
further fully differentiated in myotubes. C2C12 myotubes transfected with miR-29b mimic had a significant 
reduction in myotubes area (Fig. 8A and B), total protein concentration (Fig. 8C), number of myotubes (three 
or more nucleus/cells; Fig. 8D), and Myh7 and Myh2 expression (Fig. 8E). The miR-29b overexpression also 
repressed Col1a1 and Col3a1transcript levels (Fig. 8E).
Discussion
To the best of our knowledge, ours is the first study performing an integrated global miRNA and mRNA expres-
sion profiling in muscle of rats with CC to unravel novel regulatory networks and molecular pathways involved 
in muscle wasting. Our results highlight miRNA-regulated gene networks involved in skeletal muscle wasting in 
CC. Specifically, our results suggest that key ECM-associated miRNAs and their target genes may contribute to 
CC in HF.
Structural abnormality characteristics of skeletal myopathy have been described in CC11, 31, 32; however, tran-
scriptome profile changes associated with CC remain widely unknown. We have produced a global transcriptome 
catalogue of muscle wasting in CC that identified 1,281 differentially expressed genes, of which 538 and 743 
were up- or down-regulated, respectively. Among these, we selected the top 23 deregulated genes (p-value < 0.05 
and fold change ≥ 5); from which, 8 genes were up regulated. These most highly expressed genes revealed the 
metallothioneins (Mt1m, Mt1, and Mt2a), which are significantly increased in human skeletal muscle after 48 h 
immobilization33; these metallothioneins have also been shown to mediate protective adaptations in soleus mus-
cle following disuse mediated by spinal cord injury34 and oxidative stress protection in a mouse model of dystro-
phinopathy35. It is also noteworthy that Cyp2e1, which has been shown to impair GLUT4 gene expression and 
function in muscle cells36, had the highest fold change (46.6X) among the upregulated genes. In addition, 15 genes 
were downregulated, including mRNAs encoding ECM (Col1a1, Col3a1, and Mfap4), neuromuscular junction 
(Ky and Rab3a), IGF-1 pathway (Dok5 and Igfbp5), and myoblast proliferation proteins (Mlf1, Nrep, and Sfrp4); 
these findings are consistent with muscle fiber regeneration and ECM remodeling.
Figure 6. Complexity of the miRNA-mRNA interactome network in rat soleus muscles with cardiac cachexia. 
The regulatory network displays predicted and validated interactions between miRNAs (rectangle) and mRNAs 
(elliptic) deregulated from TLDA and microarray experiments generated by using a fold-change cutoff <1.5, 
P < 0.05 and enrichment with physical and pathway protein-protein interaction by Cytoscape database.
www.nature.com/scientificreports/
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Category analysis of the differentially expressed genes showed up-regulation of genes for catabolism (e.g., 
ubiquitin-proteasome, p53 signaling pathway, autophagy, and apoptosis) and the suppression of structural genes 
(e.g., collagen biosynthesis, regulation of myotubes differentiation, ECM organization, and muscle contraction). 
Our results are consistent with a previous meta-analysis on gene expression signatures pertaining to different 
types of muscle atrophy37. These authors described six functional pathways that occupy central positions in the 
molecular network obtained by the integration of atrophy transcriptome and interaction data. Similar to our 
study, pathway analysis of different types of muscle atrophy transcriptome indicated that deregulated genes in 
atrophy conditions are mainly involved in ECM reorganization, cytoskeleton organization, cytokines signaling, 
and apoptosis pathways37. Our results are also in agreement with a previous transcriptome analysis of skeletal 
muscle wasting performed in a transgenic mouse model of HF and CC raised by sustained activation of Met 
Tyrosine Kinase in the heart38. These authors identified 107 differentially expressed genes (fold change > 1.7) in 
CC, and the functional categories and pathways in which these differentially expressed genes were classified pre-
sented some shared core molecular mechanisms with our CC model. These include genes associated with muscle 
metabolism, growth, protein synthesis, and inflammation.
Undoubtedly, the formation, maintenance, and physiological and pathophysiological responses of skeletal 
muscles, with all their complex regulatory circuits, are subject to regulation by miRNAs. To our knowledge, ours 
is the first study that analyzed genome-wide profiling of miRNA expression during muscle wasting in CC. Using 
this analysis, we identified 18 altered miRNAs; 13 were upregulated and 5 downregulated. Previous studies have 
also reported alterations of global miRNA expression in muscle atrophy in primary muscle disorders23, diabe-
tes24, denervation24, dexamethasone-induced atrophy25, fasting24 and cancer cachexia24. The comparison of our 
CC miRNA profile with these previous studies did not reveal any similar miRNA profile but instead identified 
a specific subset of CC miRNAs. This is in line with the work by Soares et al., 201439 who did not find a com-
mon signature of miRNAs in different atrophic models (starvation, denervation, diabetes, and cancer cachexia). 
Previously, several miRNAs have also been implicated in pathological cardiac hypertrophy and HF in humans 
and in mouse models of heart disease (reviewed elsewhere40). In this sense, our findings in the skeletal muscle are 
somewhat similar to what has been found in cardiac muscle in which miRNAs add an additional layer of regula-
tion in muscle remodeling during HF.
Among the regulated skeletal muscle miRNAs in CC, we identified two upregulated miRNAs (miR-337-5p 
and miR434-3p,) that are located in the same cluster (<10 kb) and have very similar fold change values (1.98 
and 1.94, respectively). Also notable, we identified miR-29b-3p, miR-29a-3p, miR-210-3p, miR-214, and miR-
489, which had been previously reported as involved in the regulation of myogenesis41–45. Specifically, high level 
of miR-29 is important for driving myogenic differentiation, and loss of miR-29 promotes transdifferentiation 
Figure 7. Decreased collagen in the extracellular matrix in the soleus muscle of rats with cardiac cachexia. 
Analysis of type I collagen gene expression by real-time PCR (in log 2) normalized by Ppib, B2m, and Ppia 
(A). Western blot of collagen I and III normalized by β-actin (B,C). Soleus muscle cross-sections stained 
with Sirius red and analyzed in microscope under light polarized (D). Mean gray scale level of Picrosirius 
red stained collagen fibers in the soleus muscle expressed as a percent of the mean gray scale level of collagen 
in the endomysium (E). Data are expressed as mean ± SD; n = 6 per group. *p < 0.05; **p < 0.01: statistical 
significance versus CT group.
www.nature.com/scientificreports/
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of myoblasts into myofibroblasts by targeting extracellular molecules including collagens46, 47. In fact, previous 
studies have demonstrated the miR-29 family as a “master fibromiRNA” regulator of the liver, lung, skin, kidney, 
heart, and skeletal muscles fibrosis48–55. Multiple transcripts encoding standard ECM proteins such as collagens, 
fibrillins and elastin have been implicated as miR-29 family direct targets49–53. In C2C12 muscle cells, the stable 
over-expression of miR-29 down-regulates ECM and cell adhesion genes46. Most recently, Galimov et al., 201643 
used next generation RNA sequencing from miR‐29a knockout myoblasts to identified members of the basement 
membrane as the most abundant miR‐29a targets. This same study also showed that miR-29 can initiate muscle 
cell senescence leading to aging-induced atrophy by suppressing the expression of several mediators of cell prolif-
eration and muscle growth. Furthermore, in vivo studies have shown that intramuscular injection of miR-29 into 
dystrophic limb muscles down-regulated collagen and elastin mRNA expression53, whereas the systemic delivery 
of miR-29 mimics led to significant improvement of dystrophic diaphragm muscle by reducing existing fibrosis 
and increasing regeneration47. Thus, the upregulation of the miRNAs miR-29b-3p and miR-29a-3p in our model 
of CC suggest that they may have an important role in ECM remodeling in this condition.
In order to reduce the complexity of predicted miRNA-mRNA interactions identified by in silico prediction, 
and to increase the list of miRNAs targets likely associated with muscle wasting in CC, we applied an integrated 
and simultaneous mRNA and miRNA analysis. This strategy enabled us to identify biologically relevant and 
experimentally validated miRNA target genes and provided a comprehensive picture of molecular networks regu-
lated by the identified miRNAs. Specifically, this analysis identified mRNAs and miRNAs that play pivotal roles in 
Figure 8. miR-29b promotes muscle atrophy and reduces collagens expression. Immunofluorescence of 
C2C12 myotubes transfected with miR-29b-3p-mimic stained with antibodies specific to myosin heavy chain 
Myh2 (red). Nuclei stained with DAPI (blue) (A). Quantitative analyses of myotubes area (B). Total protein 
concentration in C2C12 myotubes measured by the Bradford assay (C). Number of total myotubes nuclei (three 
or more nucleus/cells) (D). mRNA levels of Col1a1, Col3a1, Myh7, and Myh2 in myotubes after miR-29b-
mimic transfection compared to their levels of expression in CT, as detected by real-time PCR. The expression 
of each transcript was normalized by the expression of Ppia and Ppib (E). Data represent the average of three 
independent experiments and are expressed as mean ± SD. *p < 0.05; **p < 0.001: statistical significance versus 
CT group.
www.nature.com/scientificreports/
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modulating diverse important biological processes in the skeletal muscle such as proteasome protein degradation 
(P = 3.2E-5), citric acid cycle and respiratory electron transport (P = 5.6E-4), JNK cascade (P = 3.4E-4), cellular 
response to TGF-β (P = 7.8E-3) and, especially, ECM organization (P = 9.2E-5). Our results showed that, com-
bined with metabolic alterations, different degradation systems and ECM remodeling are key events that likely 
contribute to skeletal muscle wasting in CC.
Several mechanisms have been proposed to explain the reduced tolerance to exercise during cardiac failure, 
focusing largely on muscle fibers intracellular alterations. The data obtained in our model, right ventricular pres-
sure overload, described in details mRNAs and miRNAs alterations that may contribute to alterations in muscle 
endomysium during CC. These results were further confirmed by a dramatic decrease in collagen deposition, 
demonstrating an actively remodeling of the ECM during skeletal muscle wasting in CC. These results differ from 
Filippatos et al., 200356 who found increased fibrosis in quadriceps muscle of HF patients with CC. Other few 
studies have analyzed the changes in the skeletal muscle ECM in CC; these alterations mainly involve enhanced 
metalloproteinase (MMP) activity and collagen content56–58. Interestingly, our data agree with recent studies that 
showed thickening of endomysium and downregulation of several ECM gene transcripts in muscle wasting in 
cancer cachexia59, 60. Considering the isolated effect of miR-29b in C2C12 myotubes, our functional experiments 
also corroborate with previous studies in C2C12 cells demonstrating that miR-29b has an anti-fibrogenic effect 
by down-regulating collagen genes46, 47 and contributes to muscle atrophy61.
To summarize, we have discovered deregulated miRNAs and their target mRNAs in CC that modulate impor-
tant biological processes in the skeletal muscle, such as proteasome protein degradation, citric acid cycle and 
respiratory electron transport, JNK cascade, cellular response to TGF-β and, importantly, ECM organization. In 
addition, our data showed that 11 miRNAs, including miR-29a-3p and miR-29b-3p, target 21 transcripts encod-
ing proteins related to ECM, comprising the collagens Col1a1, Col1a2, Col22a1, Col3a1, Col5a1, and Col6a2. 
Furthermore, the up-regulated miR-29a-3p and miR-29b-3p had the higher number of overlapping targets 
mRNAs, including target transcripts that encode ECM proteins. Herein, our integrative miRNA and mRNA anal-
ysis highlight miRNA candidates to regulate genes that may contribute to the cachectic state observed in HF.
Methods
Cardiac cachexia model. Right HF was experimentally induced in 6 male Wistar rats, 250–300 g of body 
weight, by a single intra-peritoneal (ip, 60 mg/kg) injection of monocrotaline (MCT, Sigma-Aldrich, Germany), 
following the procedure described by Gary-Bobo et al., 201062. MCT is a pyrrolizidine alkaloid that induces 
pulmonary vascular disease with severe right ventricle hypertrophy and failure63. The monocrotaline-induced 
pulmonary hypertension experimental model was used since CC is associated with right ventricular failure64. 
Moreover, this model stands out with rapidly progressive right HF and CC65, thus allowing an enhanced sensi-
tivity of detection due to larger magnitude of change in a short time frame65. Six controls rats (CT group) were 
injected with saline and were given the same quantity of food as consumed on the previous day by the rats in the 
treatment group (CC).
CC and CT rats were studied 30 days after MCT administration when the HF group had developed overt 
HF. Upon anesthesia with intraperitoneal sodium pentobarbital (50 mg/Kg), animals were euthanized and body 
weight (BW) was evaluated. Soleus muscles were excised, immediately frozen in liquid nitrogen, and stored at 
−80 °C. Left ventricle weight (LVW), right ventricle weight (RVW), and atrium weight (ATW) normalized by 
body weight (BW) were used as indexes of heart hypertrophy. Fragments of liver and lung were weighed before 
and after drying sessions (65 °C for 72 h) to evaluate wet/dry weight ratios. All experiments were carried out in 
accordance with the Guide of the Institute of Biosciences, UNESP, Botucatu, SP, Brazil. The protocol was approved 
by the Institute of Biosciences, UNESP, Botucatu, SP, Brazil (Protocol # 201).
Histochemical and morphometric procedures. Soleus histological sections (12 µm thick) from CC 
(n = 6) and CT (n = 6) were obtained in a cryostat JUNG CM1800 (Leica, Germany) at −24 °C to determine mus-
cle fiber-type frequency and cross-sectional area (CSA), using myofibrillar adenosine triphosphatase (m-ATPase) 
histochemistry after pre-incubation at pH 4.35. Muscle fiber types were classified as Types I, Ic/IIc, and IIa. Fiber 
CSA for each fiber type, and fiber-type frequencies were determined using Image Analysis System Software 
(Leica, Germany). At least 200 fibers at different points of soleus muscle were measured and their frequency was 
expressed as the number of fibers per type against the total number of fibers measured.
Electrophoretic analysis of myosin heavy chain. Myosin heavy chain (MyHC) isoform analysis was 
performed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) in triplicate. Twelve 
histological sections (12 µm thick) of CC (n = 6) and CT (n = 6) were collected from each whole muscle sample. 
The gels were stained with Coomassie Blue and used to identify the MyHC isoforms (MHC I and MyHC IIa) 
according to their molecular weight. The gels were photographed and densitometry analysis was performed using 
ImageMaster VDS Software v. 3.0 (GE, USA) to determine relative MyHC isoform content.
RNA preparations. Total RNA was isolated using TRIzol reagent (Life Technologies, USA) as described 
by the manufacturer. Total RNA was solubilized in nuclease free-water and treated to eliminate genomic DNA 
contamination with DNA-free kit (Life Technologies, USA) as described by the manufacturer. Total RNA quan-
tity was determined by the A 260 nm/A 280 nm and A 260 nm/A 230 nm ratios (acceptable when both ratios 
were > 1.8). RNA Integrity was ensured by obtaining a RNA Integrity Number - RIN > 8 with Agilent 2100 
Bioanalyzer (Agilent Technologies, Germany).
Expression profiling of miRNAs and reference genes. miRNA and mRNA was reverse transcribed 
using the Megaplex RT Primers Pools A and B and High Capacity RNA-to-cDNA master mix (Life Technologies, 
USA), respectively. Global miRNA profiling of CC (n = 6) and CT (n = 6) samples was performed with the 
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TaqMan® Array Rodent MicroRNA Cards A and B v3.0 (Life Technologies, USA) for 373 mature miRNAs in rats. 
The expression profiling of 16 mRNAs commonly used as references genes were evaluated by using the TaqMan® 
assays Low Density Array Endogenous Control Panel (Life Technologies, USA) to determine the most stable 
reference genes. miRNA and mRNAs quantitative PCR (qPCR) analyses were performed as described by the 
manufacturer and run on the ViiA™ 7 Real-Time PCR System. Finally, raw data from each card set was retrieved 
and imported into Expression Suite Software v1.0.3 (Life Technologies, USA). The small RNAs snoRNA135, Y1, 
U87, and MammU6 were selected as reference control genes to normalize the miRNA data and genes B2m, Ppia, 
and Ppib to further normalize mRNA data based on geNorm calculations66. Relative quantification of miRNA 
expression was evaluated using the comparative quantification method67. Cutoffs for significant changes were a 
fold-change > 1.5 and a p-value ≤ 0.05.
Quantitative analyses of gene expression by real-time reverse transcription polymerase chain 
reaction (RT-qPCR). RT-qPCR was carried out with GoTaq® qPCR Master Mix (Promega, USA), using 
specifics primers (Supplementary Table S9) and cDNA of each sample of CC (n = 6) and CT (n = 6) groups. 
Reactions were set up in a total volume of 20 µL and performed in the ABI Prism 7300 real-time PCR system 
(Life Technologies, USA) as described by the manufacturer. Relative quantification of mRNA expression by SYBR 
green I were assessed by using REST software 2009 v2.0.13, using the pair-wise fixed randomization test with 
10,000 permutations68, with PCR efficiencies calculated by linear regression from fluorescence increase in the 
exponential phase in the program LinRegPCR v11.169. Cutoffs for significant changes were a fold-change > 1.5 
and a p-value ≤ 0.05.
Global gene expression profiling analysis. Gene expression profiling of CC (n = 3) and CT (n = 3) 
groups was performed using the Rat Gene 1.0 ST Array platform (Affymetrix, USA) that covers 17,061 RefSeq 
transcripts, according to the manufacturer’s instructions. The Ambion WT Expression Kit (Life Technologies, 
Carlsbad, CA, USA) was used to cDNA synthesis and cRNA amplification, while the fragmentation and labeling 
procedures were performed with the Affymetrix GeneChip WT Terminal Labeling Kit. Arrays hybridization, 
washing and scanning were carried on the Affymetrix GeneChip Hybridization Oven 645, Fluidic Station 450 and 
Scanner 3000 7 G, respectively. Quality control and probe set summarization to attain gene-level signal data was 
provided by Affymetrix Expression Console software. Data analysis was performed with the R language (v.2.13.0). 
Background correction and quartile data normalization were applied using RMA (Robust Multi-array Average) 
algorithm70. The limma Bioconductor package71 was used to identify differential expressed genes (DEG). Cutoffs 
for significant changes were a fold-change > 1.5 and a p-value ≤ 0.05.
Western Blot analysis. Protein levels of soleus muscle of CC and CT samples were analyzed by Western 
blotting using antibodies specific for collagen I (1:100) (sc-25974, Santa Cruz) and collagen III (1:5000) (ab6310, 
Abcam). Protein levels were normalized by the endogenous β-actin (1:1000) (sc-81178, Santa Cruz). Muscle 
protein was extracted using Tris-Triton buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) containing Protease Inhibitor Cocktail (Sigma- 
Aldrich, USA) and quantified by the Bradford method72. Samples were separated on a polyacrylamide gel and 
then transferred to a nitrocellulose membrane. After blockage, membranes were incubated with the primary 
antibody. Membrane was washed with TBS-T and incubated with secondary peroxidase-conjugated antibody 
(1:2500). Super Signal® West Pico Chemiluminescent Substrate (Pierce Protein Research Products, Rockford, 
USA) was used to detect bound antibodies.
Pathway and gene ontology enrichment analysis. To further understand the biological relevance of 
differential expressed genes, we performed functional enrichment analysis in the context of the Gene Ontology 
(GO) categories, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases. A p-value cut-off 
of 0.001 was used to identify enriched processes. A kappa score was calculated to reflect the relationships between 
the terms based on the similarity of their associated genes, PSIQUIC web services with the threshold set at 0.3. 
was used to provide a comprehensive view on the relevant pathways using experimental and in silico data from 
gene networks, protein–protein interactions, and functional interactions73, 74. Networks were visualized and ana-
lyzed with Cytoscape75.
miRNA – target gene network. Candidate miRNA–target relationships were assessed by at least four tar-
get prediction algorithms (union set) extracted from: mirDB, TargetScan 5.1 (conservation and non-conservation 
sites) (www.targetscan.com), DIANA-microT-CDS v576, miRWalK v2.077, and miRanda78. Additionally, we used 
validated targets deposited in miRTarBase79, miRecords80, and miRwalK81. To avoid target multiplicity, we con-
structed miRNA target–gene networks considering differentially expressed genes identified by cDNA microarray 
experimental data.
Determination of collagen content. Collagen content in soleus muscle was determined using Picrosirius 
red staining. Briefly, transverse cryosections (12 μm thick) of all samples were placed on the same slide to mini-
mize staining differences; sections were incubated with saturated picric acid solution followed by Picrosirius red 
(0.1% Sirius red in saturated picric acid) for 3 min., dehydrated and mounted in Permount. Eight color pictures 
per sample were captured using the microscope with polarized light (400X magnification). Light intensity and 
filters alignment parameters used were the same for all samples. Quantitative analysis of endomysium collagen 
type I staining intensity was determined by measuring the grayscale with the Image Analysis System Software 
(Leica, Germany). The gray values were normalized by mean fiber area.
www.nature.com/scientificreports/
1 1SCIENtIFIC RePoRtS | 7: 6998 | DOI:10.1038/s41598-017-07236-2
Oligonucleotides and transfection. The miR-29b-3p mimic and the respective negative control were 
complexed with Opti-MEM reduced serum medium (Thermo Fisher Scientific, USA) before transfection. C2C12 
myoblasts transfections were performed, when the cells were at approximately 80% confluent, with RNAiMAX 
lipofectamine (Thermo Fisher Scientific, USA) combined with 30 nM of each oligonucleotide for 15 h. Myoblasts 
were switched to medium containing 2% horse serum to induce differentiation into myotubes. Myotube area, total 
protein concentration, number of myotubes, and gene expression were analyzed after 5 days of differentiation.
Immunostaining. C2C12 myotubes cultured in 6-well plates were fixed in 4% paraformaldehyde for 15 min, 
washed with PBS and 0.1% TritonX-100 (Sigma, USA), and blocked with 3% BSA, 1% glycine, 8% fetal bovine 
serum in PBS and 0.1% TritonX-100 for 1 h at room temperature. Subsequently, the cells were incubated with pri-
mary (Myh) antibodies overnight at 4 °C and, after washing, the cells were incubated with secondary antibodies 
for 1 h at room temperature and counterstained with DAPI. All images were acquired at room temperature by 
scanning confocal microscope TCS SP5 (Leica Microsystems, UK). Myotubes area and number of nuclei were 
measured by ImageJ software (National Institutes of Health, USA).
Statistical analysis. Data were expressed as mean ± standard deviation (SD). Statistical analysis was per-
formed using the GraphPad Prisma software v 6.07 (GraphPad Software, Inc., USA). For all statistical analyses not 
described elsewhere, we used an unpaired, Mann Whitney test. Statistical significance was considered achieved 
when the p-value was <0.05.
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